Free Trial

Teva Pharmaceutical Industries Ltd. $TEVA Stock Sold by William Blair Investment Management LLC

Teva Pharmaceutical Industries logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • William Blair Investment Management cut its Teva stake by 7.2%, selling 474,249 shares in the third quarter; it retained about 6.12 million shares, worth approximately $242.3 million.
  • Teva reported quarterly earnings of $0.86 per share, above the $0.72 consensus, and revenue of $4.39 billion, also ahead of estimates; revenue declined 1.9% year over year.
  • Analysts’ consensus rating was “Moderate Buy,” with an average price target of $48.15. Separately, company insiders sold a combined 715,945 shares over the past three months.
  • MarketBeat previews top five stocks to own in December.

William Blair Investment Management LLC cut its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 7.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,118,972 shares of the company's stock after selling 474,249 shares during the quarter. Teva Pharmaceutical Industries accounts for 0.8% of William Blair Investment Management LLC's holdings, making the stock its 22nd biggest position. William Blair Investment Management LLC owned 0.53% of Teva Pharmaceutical Industries worth $242,311,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of TEVA. Root Financial Partners LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $33,000. Cornerstone Planning Group LLC increased its stake in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $43,000. Sunbelt Securities Inc. acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $45,000. Finally, CX Institutional acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth $54,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $44.52 on Monday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The stock has a market cap of $51.88 billion, a price-to-earnings ratio of 103.53, a PEG ratio of 3.85 and a beta of 0.97. The business has a 50 day simple moving average of $40.16 and a 200 day simple moving average of $35.07. Teva Pharmaceutical Industries Ltd. has a 52-week low of $24.01 and a 52-week high of $44.57.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business's revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.78 earnings per share. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent analyst reports. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday, September 4th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an "overweight" rating in a research report on Thursday, October 15th. Leerink Partners raised their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, November 5th. Weiss Ratings raised Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, November 4th. Finally, Oppenheimer lifted their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a report on Friday, October 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $48.15.

Read Our Latest Analysis on Teva Pharmaceutical Industries

Insider Activity at Teva Pharmaceutical Industries

In related news, CEO Richard D. Francis sold 250,000 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total value of $10,560,000.00. Following the completion of the transaction, the chief executive officer directly owned 927,529 shares of the company's stock, valued at approximately $39,178,824.96. This represents a 21.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 46,000 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the transaction, the insider owned 80,760 shares of the company's stock, valued at approximately $3,386,266.80. This trade represents a 36.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 715,945 shares of company stock valued at $29,061,351 over the last three months. Insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Recommended Stories

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines